Director/PDMR Shareholding

Summary by AI BETAClose X

GSK plc has reported several transactions by its Persons Disclosing Management and Related Persons (PDMRs). Sir Jonathan Symonds, Non-Executive Chair, purchased 1,550 ordinary shares on June 19, 2026, for £19.3524 per share on the London Stock Exchange. On June 22, 2026, Independent Non-Executive Directors Elizabeth McKee Anderson, Charles Bancroft, Dr. Anne Beal, Dr. Hal Dietz, Dr. Jeannie Lee, and Dr. Vishal Sikka purchased American Depositary Shares (ADS) on the New York Stock Exchange at $50.6908 per ADS, with volumes of 789, 1,855, 745, 667, 802, and 1,266 respectively. These purchases represent an investment by key personnel in the company.

Disclaimer*

GSK PLC
23 June 2026
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Jonathan Symonds

b)

Position/status

Non-Executive Chair

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Purchase of 1,550 Ordinary Shares

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£19.3524

1,550






d)

Aggregated information

 

 

N/A (single transaction)

 

 

Aggregated volume Price


e)

Date of the transaction

2026-06-19

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Elizabeth (Liz) McKee Anderson

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 789 ADS

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.6908

 

789






d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Charles Bancroft

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 1,855 ADS

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.6908

1,855






d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Anne Beal

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 745 ADS

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.6908

745






d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Dietz

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 667 ADS

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.6908

667






d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Jeannie Lee

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 802 ADS

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.6908

802






d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Vishal Sikka

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 1,266 ADS

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$50.6908

1,266






d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price


e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

GSK (GSK)
UK 100

Latest directors dealings